Patient entry completed for Phase III trial programme in Hepatitis C
9 December 2011 | By Boehringer Ingelheim
The final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335...
List view / Grid view
9 December 2011 | By Boehringer Ingelheim
The final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335...
8 December 2011 | By AstraZeneca
AstraZeneca to acquire Guangdong BeiKang Pharmaceutical Company Ltd...
8 December 2011 | By AstraZeneca
Company will reduce its US sales force by approximately 1,150 leadership positions and sales representatives...
8 December 2011 | By GlaxoSmithKline
Results from TEACH were presented at the 2011 CRTC-AACR San Antonio Breast Cancer Symposium...
8 December 2011 | By Virgo HEALTH
The European Commission has granted marketing authorisation for Edarbi® (azilsartan medoxomil)...
8 December 2011 | By Abbott
Abbott today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial...
8 December 2011 | By Roche
6.1 month improvement in median progression free survival, from 12.4 to 18.5 months...
8 December 2011 | By Johnson & Johnson
Compound in development for multiple B-cell hematologic malignancies...
8 December 2011 | By Novartis
Updated results of a Phase III study...
7 December 2011 | By kdm communications limited
Syrris is pleased to announce the release of its new batch chemistry reactors catalogue...
6 December 2011 | By kdm communications limited
Infinite M1000 PRO is Tecan’s latest generation high-end multimode microplate reader...
6 December 2011 | By Merck Millipore
Experts from around the world share perspectives and insights on topics related to process-scale chromatography...
6 December 2011 | By MSD
Data presented at the IDF 21st World Diabetes Congress...
6 December 2011 | By Novo Nordisk
Insulin degludec / insulin aspart reduced rates of hypoglycaemia by 58%...
6 December 2011 | By
Commits $1.5 billion to R&D in China over the next 5 years...